



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Chesie Voma

PATIENT

DEMOGRAPHICS

Patient Name: RONALD ZEKA	Account: Desert Kidney Associates Baseline	Order Code: 2021-0011943
DOB: 04/15/1948	Provider: Thaddeo Oconer	Sample Type: Urine
Patient Gender: M	Accession: 21121300091	Collected: 12/09/2021
Patient Phone Number: (480) 239-1886	Report Status:	Received: 2021-12-13T15:38:52.157585
		Reported: 04/05/2022

PRESCRIPTION

LIST

Acetaminophen (Tylenol) , Losartan (Cozaar) , Metoprolol (Lopressor , Toprol XL) , Atorvastatin (Lipitor) , Omeprazole (Prilosec , Prilosec OTC , Zegerid OTC , OmePPI) , Doxycycline (Doxy-100 , Monodox , Targadox , Acticlate , Adoxa CK , Adoxa Pak , Adoxa TT , Alodox , Avidoxy , Doryx , Mondoxyne NL , Morgidox , Okebo , Oracea , Oraxyl , Periostat , Vibramycin calcium , Vibramycin Hyclate , Vibramycin monohydrate , Vibra-Tabs)	Z51.81, Z79.899, I10 Hypertension, N18.30
--	---

INCONSISTENT				INCONSISTENT				
NOT PRESCRIBED			DETECTED	PRESCRIBED			NOT DETECTED	
Class	Test	Cutoff (ng/mL)	Results (ng/mL)	Class	Test	Cutoff (ng/mL)		
DIURETIC	Hydrochlorothiazide	50	22919.24	NSAID	Acetaminophen	400		
	[CI] Chronic kidney disease, stage 3 unspecified 				[DDI] The metabolism of Atorvastatin can be decreased when combined with Acetaminophen. Hydrochlorothiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. Doxycycline may decrease the excretion rate of Acetaminophen which could result in a higher serum level. The metabolism of Acetaminophen can be decreased when combined with Metoprolol. The metabolism of Acetaminophen can be increased when combined with Omeprazole.			
	[CI] Chronic kidney disease, stage 3 unspecified 				[DDI] The metabolism of Atorvastatin can be decreased when combined with Acetaminophen. Hydrochlorothiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. Doxycycline may decrease the excretion rate of Acetaminophen which could result in a higher serum level. The metabolism of Acetaminophen can be decreased when combined with Metoprolol. The metabolism of Acetaminophen can be increased when combined with Omeprazole.			
	[CI] Chronic kidney disease, stage 3 unspecified 				[DDI] The metabolism of Atorvastatin can be decreased when combined with Acetaminophen. Hydrochlorothiazide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.			
	[CI] Chronic kidney disease, stage 3 unspecified				[DDI] Doxycycline may decrease the excretion rate of Acetaminophen which could result in a higher serum level.			
				STATIN	Atorvastatin	10		
					[DDI] Metoprolol may increase the arrhythmogenic activities of Losartan. The metabolism of Atorvastatin can be decreased when combined with Losartan. The metabolism of Omeprazole can be decreased when combined with Losartan.			
					[DDI] Metoprolol may increase the arrhythmogenic activities of Losartan. The metabolism of Atorvastatin can be decreased when combined with Losartan. The metabolism of Omeprazole can be decreased when combined with Losartan.			
					[DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan.			
					[DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan.			
					[DDI] The metabolism of Atorvastatin can be decreased when combined with Omeprazole.			
					[DDI] The metabolism of Atorvastatin can be decreased when combined with Omeprazole.			
					[DDI] The metabolism of Atorvastatin can be decreased when combined with Omeprazole.			
					[DDI] The metabolism of Atorvastatin can be decreased when combined with Omeprazole.			
					[DDI] The metabolism of Atorvastatin can be decreased when combined with Omeprazole.			

CONTRAINDICATION		NOT TESTED
Drug	Contraindication	
Losartan	[DDI] The metabolism of Omeprazole can be decreased when combined with Losartan. [DDI] The metabolism of Omeprazole can be decreased when combined with Losartan.	

CONSISTENT				VALIDITY TESTING & SCREENS		
PRESCRIBED			DETECTED	Specimen Validity	Range	Results
Class	Test	Cutoff (ng/mL)	Results (ng/mL)	PH	4.50 - 8.00	5.7
BETA BLOCKER	Metoprolol	50	4636.70	Specific Gravity	1.01 - 1.03	1.019
	[DDI] The metabolism of Metoprolol can be decreased when combined with Omeprazole.			Urine Creatinine (mg/dL)	20.00 - 400.00	138.35
	[DDI] The metabolism of Metoprolol can be decreased when combined with Omeprazole.					
	[DDI] The metabolism of Metoprolol can be decreased when combined with Omeprazole.					
	[DDI] Metoprolol may increase the arrhythmogenic activities of Losartan.					
	[DDI] Metoprolol may increase the arrhythmogenic activities of Losartan.					



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Chesie Voma

PATIENT

DEMOGRAPHICS

Patient Name: RONALD ZEKA	Account: Desert Kidney Associates Baseline	Order Code: 2021-0011943
DOB: 04/15/1948	Provider: Thaddeo Oconer	Sample Type: Urine
Patient Gender: M	Accession: 21121300091	Collected: 12/09/2021
Patient Phone Number: (480) 239-1886	Report Status:	Received: 2021-12-13T15:38:52.157585
		Reported: 04/05/2022

NOT PRESCRIBED				NOT DETECTED			
Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)
Gabapentin	1000	Norhydrocodone	50	Duloxetine	50	Sertraline	50
Glipizide	10	Norhydromorphone		4-Hydroxydiclofenac	50	Sitagliptin	50
Glyburide	10	Normeperidine	100	Tapentadol	50	Sumatriptan	50
Haloperidol	25	Noroxycodone	50	Temazepam	40	Zolmitriptan	50
Hydrocodone	50	Noroxymorphone		THC-COOH	50	Bupropion	
Hydromorphone	50	Norpropoxyphene	100	Topiramate	50	Buspirone	50
Hydroxybupropion	50	Nortriptyline	50	Tramadol	100	Caffeine	50
Ibuprofen		Norverapamil	50	Trazodone	50	Carbamazepine	50
Imipramine	50	O-Desmethyltramadol	100	Valsartan	50	Carbamazepine Epoxide	
Indomethacin	50	O-Desmethylvenlafaxine	100	Venlafaxine	100	Carboxyclopidogrel	50
Irbesartan	50	Olanzapine	25	7-Aminoclonazepam	40	Carisoprodol	100
Levetiracetam	50	Oxazepam	40	9-Hydroxyrisperidone	10	Celecoxib	50
Lisinopril	50	Oxycodone	50	alpha-Hydroxyalprazolam	30	Chlorpromazine	25
Lorazepam	40	Oxymorphone	50	Alprazolam	30	Citalopram	
Lurasidone	25	Paroxetine	25	Amitriptyline	50	Clonazepam	20
Meperidine		Phentermine	100	Amlodipine	25	Clonidine	50
Meprobamate	200	Pioglitazone	50	Aripiprazole	20	Clopidogrel	
Metformin	500	Pitavastatin	10	Atenolol	50	Clozapine	
Methylphenidate		Pregabalin	150	Atomoxetine	50	Codeine	50
Mirtazapine		Propoxyphene		Baclofen	50	Cotinine	50
Morphine	50	Verapamil		Buprenorphine	10	Cyclobenzaprine	50
Naloxone	10	Warfarin	10	Propranolol	50	Dehydroaripiprazole	20
Naproxen	100	Ziprasidone	25	Protriptyline	50	Desipramine	50
N-Desmethylcitalopram	50	Amphetamine	200	Pseudoephedrine	50	Diazepam	10
N-Desmethylclozapine	25	Digoxin	10	Quetiapine	50	Diclofenac	50
N-Desmethylmirtazapine	25	Dihydrocodeine	50	Risperidone	10	Ethyl Glucuronide	
N-Desmethylolanzapine	25	Diltiazem	50	Ritalinic Acid		Ethyl Sulfate	
Norbuprenorphine	30	Diphenhydramine	50	Rivaroxaban	50	Fentanyl	2
Nordiazepam	40	Donepezil	50	Rosuvastatin	20	Fluoxetine	25
Norfentanyl	8	Doxepin	30	Salicylic Acid	400		

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.